Selected research
Market Structure
Global Chronic Idiopathic Constipation Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Chronic Idiopathic Constipation Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Chronic Idiopathic Constipation Drugs include Sanofi, Merck, Eli Lilly, Pfizer, Glaxosmithkline, Bayer AG, Theravance Biopharma Inc, Synergy Pharmaceuticals and Sucampo Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Chronic Idiopathic Constipation Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Chronic Idiopathic Constipation Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Chronic Idiopathic Constipation Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Idiopathic Constipation Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Chronic Idiopathic Constipation Drugs Segment by Company
Sanofi
Merck
Eli Lilly
Pfizer
Glaxosmithkline
Bayer AG
Theravance Biopharma Inc
Synergy Pharmaceuticals
Sucampo Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Roche Holding AG
Progenics Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Ferring International Center S.A
Daiichi Sankyo
Cosmo Pharmaceuticals SA
Chugai Pharmaceutical
Bausch Health
Allergens
Chronic Idiopathic Constipation Drugs Segment by Type
Linaclotide
Lubiprostone
Others
Chronic Idiopathic Constipation Drugs Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Chronic Idiopathic Constipation Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Idiopathic Constipation Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Idiopathic Constipation Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Idiopathic Constipation Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chronic Idiopathic Constipation Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Idiopathic Constipation Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chronic Idiopathic Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Chronic Idiopathic Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Chronic Idiopathic Constipation Drugs Industry Trends
Table 2. Chronic Idiopathic Constipation Drugs Industry Drivers
Table 3. Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges
Table 4. Chronic Idiopathic Constipation Drugs Industry Restraints
Table 5. Global Chronic Idiopathic Constipation Drugs Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Chronic Idiopathic Constipation Drugs Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Manufacturers
Table 9. Global Chronic Idiopathic Constipation Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Chronic Idiopathic Constipation Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Chronic Idiopathic Constipation Drugs Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Chronic Idiopathic Constipation Drugs Manufacturers, Product Type & Application
Table 13. Global Chronic Idiopathic Constipation Drugs Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Chronic Idiopathic Constipation Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Linaclotide
Table 17. Major Manufacturers of Lubiprostone
Table 18. Major Manufacturers of Others
Table 19. Global Chronic Idiopathic Constipation Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 20. Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2026) & (K Units)
Table 21. Global Chronic Idiopathic Constipation Drugs Sales by Type (2027-2032) & (K Units)
Table 22. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2026)
Table 23. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2027-2032)
Table 24. Global Chronic Idiopathic Constipation Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 25. Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021-2026) & (K Units)
Table 26. Global Chronic Idiopathic Constipation Drugs Revenue by Type (2027-2032) & (K Units)
Table 27. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2026)
Table 28. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2027-2032)
Table 29. Major Manufacturers of Retail Pharmacies
Table 30. Major Manufacturers of Online Pharmacies
Table 31. Major Manufacturers of Hospital Pharmacies
Table 32. Global Chronic Idiopathic Constipation Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 33. Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2026) & (K Units)
Table 34. Global Chronic Idiopathic Constipation Drugs Sales by Application (2027-2032) & (K Units)
Table 35. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2026)
Table 36. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2027-2032)
Table 37. Global Chronic Idiopathic Constipation Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 38. Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021-2026) & (K Units)
Table 39. Global Chronic Idiopathic Constipation Drugs Revenue by Application (2027-2032) & (K Units)
Table 40. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2026)
Table 41. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2027-2032)
Table 42. Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 43. Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2026) & (K Units)
Table 44. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region (2021-2026)
Table 45. Global Chronic Idiopathic Constipation Drugs Sales Forecasted by Region (2027-2032) & (K Units)
Table 46. Global Chronic Idiopathic Constipation Drugs Sales Forecasted Market Share by Region (2027-2032)
Table 47. North America Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 48. North America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 49. North America Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 50. Europe Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 51. Europe Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 52. Europe Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 53. Asia Pacific Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 54. Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 55. Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 56. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 57. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units)
Table 58. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units)
Table 59. Global Chronic Idiopathic Constipation Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 60. Global Chronic Idiopathic Constipation Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 61. Global Chronic Idiopathic Constipation Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 62. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region (2021-2026)
Table 63. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region (2027-2032)
Table 64. Sanofi Company Information
Table 65. Sanofi Business Overview
Table 66. Sanofi Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 67. Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio
Table 68. Sanofi Recent Development
Table 69. Merck Company Information
Table 70. Merck Business Overview
Table 71. Merck Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 72. Merck Chronic Idiopathic Constipation Drugs Product Portfolio
Table 73. Merck Recent Development
Table 74. Eli Lilly Company Information
Table 75. Eli Lilly Business Overview
Table 76. Eli Lilly Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio
Table 78. Eli Lilly Recent Development
Table 79. Pfizer Company Information
Table 80. Pfizer Business Overview
Table 81. Pfizer Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 82. Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio
Table 83. Pfizer Recent Development
Table 84. Glaxosmithkline Company Information
Table 85. Glaxosmithkline Business Overview
Table 86. Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 87. Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio
Table 88. Glaxosmithkline Recent Development
Table 89. Bayer AG Company Information
Table 90. Bayer AG Business Overview
Table 91. Bayer AG Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 92. Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio
Table 93. Bayer AG Recent Development
Table 94. Theravance Biopharma Inc Company Information
Table 95. Theravance Biopharma Inc Business Overview
Table 96. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 97. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 98. Theravance Biopharma Inc Recent Development
Table 99. Synergy Pharmaceuticals Company Information
Table 100. Synergy Pharmaceuticals Business Overview
Table 101. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 102. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio
Table 103. Synergy Pharmaceuticals Recent Development
Table 104. Sucampo Pharmaceuticals Inc Company Information
Table 105. Sucampo Pharmaceuticals Inc Business Overview
Table 106. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 107. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 108. Sucampo Pharmaceuticals Inc Recent Development
Table 109. Salix Pharmaceuticals Ltd Company Information
Table 110. Salix Pharmaceuticals Ltd Business Overview
Table 111. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 112. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio
Table 113. Salix Pharmaceuticals Ltd Recent Development
Table 114. Roche Holding AG Company Information
Table 115. Roche Holding AG Business Overview
Table 116. Roche Holding AG Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 117. Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio
Table 118. Roche Holding AG Recent Development
Table 119. Progenics Pharmaceuticals Inc Company Information
Table 120. Progenics Pharmaceuticals Inc Business Overview
Table 121. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 122. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 123. Progenics Pharmaceuticals Inc Recent Development
Table 124. Ironwood Pharmaceuticals Inc Company Information
Table 125. Ironwood Pharmaceuticals Inc Business Overview
Table 126. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 127. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
Table 128. Ironwood Pharmaceuticals Inc Recent Development
Table 129. Ferring International Center S.A Company Information
Table 130. Ferring International Center S.A Business Overview
Table 131. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 132. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio
Table 133. Ferring International Center S.A Recent Development
Table 134. Daiichi Sankyo Company Information
Table 135. Daiichi Sankyo Business Overview
Table 136. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 137. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio
Table 138. Daiichi Sankyo Recent Development
Table 139. Cosmo Pharmaceuticals SA Company Information
Table 140. Cosmo Pharmaceuticals SA Business Overview
Table 141. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 142. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio
Table 143. Cosmo Pharmaceuticals SA Recent Development
Table 144. Chugai Pharmaceutical Company Information
Table 145. Chugai Pharmaceutical Business Overview
Table 146. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 147. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio
Table 148. Chugai Pharmaceutical Recent Development
Table 149. Bausch Health Company Information
Table 150. Bausch Health Business Overview
Table 151. Bausch Health Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 152. Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio
Table 153. Bausch Health Recent Development
Table 154. Allergens Company Information
Table 155. Allergens Business Overview
Table 156. Allergens Chronic Idiopathic Constipation Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 157. Allergens Chronic Idiopathic Constipation Drugs Product Portfolio
Table 158. Allergens Recent Development
Table 159. Key Raw Materials
Table 160. Raw Materials Key Suppliers
Table 161. Chronic Idiopathic Constipation Drugs Distributors List
Table 162. Chronic Idiopathic Constipation Drugs Customers List
Table 163. Research Programs/Design for This Report
Table 164. Authors List of This Report
Table 165. Secondary Sources
Table 166. Primary Sources
List of Figures
Figure 1. Chronic Idiopathic Constipation Drugs Product Image
Figure 2. Global Chronic Idiopathic Constipation Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Chronic Idiopathic Constipation Drugs Market Size (2021-2032) & (US$ Million)
Figure 4. Global Chronic Idiopathic Constipation Drugs Sales (2021-2032) & (K Units)
Figure 5. Global Chronic Idiopathic Constipation Drugs Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Chronic Idiopathic Constipation Drugs Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Linaclotide Image
Figure 9. Lubiprostone Image
Figure 10. Others Image
Figure 11. Global Chronic Idiopathic Constipation Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 12. Global Chronic Idiopathic Constipation Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 13. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2032)
Figure 14. Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 15. Global Chronic Idiopathic Constipation Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 16. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2032)
Figure 17. Retail Pharmacies Image
Figure 18. Online Pharmacies Image
Figure 19. Hospital Pharmacies Image
Figure 20. Global Chronic Idiopathic Constipation Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 21. Global Chronic Idiopathic Constipation Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 22. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2032)
Figure 23. Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 24. Global Chronic Idiopathic Constipation Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 25. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2032)
Figure 26. North America Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 27. North America Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 28. U.S. Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 29. Canada Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. Mexico Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Europe Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Europe Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 33. Germany Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 34. France Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. U.K. Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. Italy Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. Netherlands Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Asia Pacific Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Asia Pacific Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 40. China Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 41. Japan Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. South Korea Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. Southeast Asia Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. India Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. Australia Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2032)
Figure 48. Brazil Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 49. South Africa Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. Saudi Arabia Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. Turkey Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. Argentina Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. UAE Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. Egypt Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Chile Chronic Idiopathic Constipation Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Global Chronic Idiopathic Constipation Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 57. Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 58. North America Chronic Idiopathic Constipation Drugs Revenue (2021-2032) & (US$ Million)
Figure 59. North America Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 60. Europe Chronic Idiopathic Constipation Drugs Revenue (2021-2032) & (US$ Million)
Figure 61. Europe Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 62. Asia-Pacific Chronic Idiopathic Constipation Drugs Revenue (2021-2032) & (US$ Million)
Figure 63. Asia-Pacific Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 64. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue (2021-2032) & (US$ Million)
Figure 65. South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 66. Chronic Idiopathic Constipation Drugs Value Chain
Figure 67. Manufacturing Cost Structure
Figure 68. Chronic Idiopathic Constipation Drugs Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
Scope & coverage.
Types
- Linaclotide
- Lubiprostone
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Sanofi
- Merck
- Eli Lilly
- Pfizer
- Glaxosmithkline
- Bayer AG
- Theravance Biopharma Inc
- Synergy Pharmaceuticals
- Sucampo Pharmaceuticals Inc
- Salix Pharmaceuticals Ltd
- Roche Holding AG
- Progenics Pharmaceuticals Inc
- Ironwood Pharmaceuticals Inc
- Ferring International Center S.A
- Daiichi Sankyo
- Cosmo Pharmaceuticals SA
- Chugai Pharmaceutical
- Bausch Health
- Allergens
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Chronic Idiopathic Constipation Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Chronic Idiopathic Constipation Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Chronic Idiopathic Constipation Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Chronic Idiopathic Constipation Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Chronic Idiopathic Constipation Drugs Market Dynamics
- 2.1 Chronic Idiopathic Constipation Drugs Industry Trends
- 2.2 Chronic Idiopathic Constipation Drugs Industry Drivers
- 2.3 Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges
- 2.4 Chronic Idiopathic Constipation Drugs Industry Restraints
3 Chronic Idiopathic Constipation Drugs Market by Manufacturers
- 3.1 Global Chronic Idiopathic Constipation Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Chronic Idiopathic Constipation Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Chronic Idiopathic Constipation Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Chronic Idiopathic Constipation Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Chronic Idiopathic Constipation Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Chronic Idiopathic Constipation Drugs Manufacturers, Product Type & Application
- 3.7 Global Chronic Idiopathic Constipation Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Chronic Idiopathic Constipation Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Chronic Idiopathic Constipation Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Chronic Idiopathic Constipation Drugs Tier 1, Tier 2, and Tier 3
4 Chronic Idiopathic Constipation Drugs Market by Type
- 4.1 Chronic Idiopathic Constipation Drugs Type Introduction
- 4.1.1 Linaclotide
- 4.1.2 Lubiprostone
- 4.1.3 Others
- 4.2 Global Chronic Idiopathic Constipation Drugs Sales by Type
- 4.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Chronic Idiopathic Constipation Drugs Sales by Type (2021-2032)
- 4.2.3 Global Chronic Idiopathic Constipation Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Chronic Idiopathic Constipation Drugs Revenue by Type
- 4.3.1 Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Chronic Idiopathic Constipation Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Type (2021-2032)
5 Chronic Idiopathic Constipation Drugs Market by Application
- 5.1 Chronic Idiopathic Constipation Drugs Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Hospital Pharmacies
- 5.2 Global Chronic Idiopathic Constipation Drugs Sales by Application
- 5.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Chronic Idiopathic Constipation Drugs Sales by Application (2021-2032)
- 5.2.3 Global Chronic Idiopathic Constipation Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Chronic Idiopathic Constipation Drugs Revenue by Application
- 5.3.1 Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Chronic Idiopathic Constipation Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Application (2021-2032)
6 Global Chronic Idiopathic Constipation Drugs Sales by Region
- 6.1 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2032)
- 6.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2026)
- 6.2.2 Global Chronic Idiopathic Constipation Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Chronic Idiopathic Constipation Drugs Revenue by Region
- 7.1 Global Chronic Idiopathic Constipation Drugs Revenue by Region
- 7.1.1 Global Chronic Idiopathic Constipation Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Chronic Idiopathic Constipation Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Chronic Idiopathic Constipation Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Chronic Idiopathic Constipation Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Chronic Idiopathic Constipation Drugs Revenue (2021-2032)
- 7.2.2 North America Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Chronic Idiopathic Constipation Drugs Revenue (2021-2032)
- 7.3.2 Europe Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Chronic Idiopathic Constipation Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Chronic Idiopathic Constipation Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Eli Lilly
- 8.3.1 Eli Lilly Company Information
- 8.3.2 Eli Lilly Business Overview
- 8.3.3 Eli Lilly Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.3.5 Eli Lilly Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Company Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 Glaxosmithkline
- 8.5.1 Glaxosmithkline Company Information
- 8.5.2 Glaxosmithkline Business Overview
- 8.5.3 Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.5.5 Glaxosmithkline Recent Developments
- 8.6 Bayer AG
- 8.6.1 Bayer AG Company Information
- 8.6.2 Bayer AG Business Overview
- 8.6.3 Bayer AG Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.6.5 Bayer AG Recent Developments
- 8.7 Theravance Biopharma Inc
- 8.7.1 Theravance Biopharma Inc Company Information
- 8.7.2 Theravance Biopharma Inc Business Overview
- 8.7.3 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.7.5 Theravance Biopharma Inc Recent Developments
- 8.8 Synergy Pharmaceuticals
- 8.8.1 Synergy Pharmaceuticals Company Information
- 8.8.2 Synergy Pharmaceuticals Business Overview
- 8.8.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.8.5 Synergy Pharmaceuticals Recent Developments
- 8.9 Sucampo Pharmaceuticals Inc
- 8.9.1 Sucampo Pharmaceuticals Inc Company Information
- 8.9.2 Sucampo Pharmaceuticals Inc Business Overview
- 8.9.3 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.9.5 Sucampo Pharmaceuticals Inc Recent Developments
- 8.10 Salix Pharmaceuticals Ltd
- 8.10.1 Salix Pharmaceuticals Ltd Company Information
- 8.10.2 Salix Pharmaceuticals Ltd Business Overview
- 8.10.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.10.5 Salix Pharmaceuticals Ltd Recent Developments
- 8.11 Roche Holding AG
- 8.11.1 Roche Holding AG Company Information
- 8.11.2 Roche Holding AG Business Overview
- 8.11.3 Roche Holding AG Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.11.5 Roche Holding AG Recent Developments
- 8.12 Progenics Pharmaceuticals Inc
- 8.12.1 Progenics Pharmaceuticals Inc Company Information
- 8.12.2 Progenics Pharmaceuticals Inc Business Overview
- 8.12.3 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.12.5 Progenics Pharmaceuticals Inc Recent Developments
- 8.13 Ironwood Pharmaceuticals Inc
- 8.13.1 Ironwood Pharmaceuticals Inc Company Information
- 8.13.2 Ironwood Pharmaceuticals Inc Business Overview
- 8.13.3 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.13.5 Ironwood Pharmaceuticals Inc Recent Developments
- 8.14 Ferring International Center S.A
- 8.14.1 Ferring International Center S.A Company Information
- 8.14.2 Ferring International Center S.A Business Overview
- 8.14.3 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.14.5 Ferring International Center S.A Recent Developments
- 8.15 Daiichi Sankyo
- 8.15.1 Daiichi Sankyo Company Information
- 8.15.2 Daiichi Sankyo Business Overview
- 8.15.3 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.15.5 Daiichi Sankyo Recent Developments
- 8.16 Cosmo Pharmaceuticals SA
- 8.16.1 Cosmo Pharmaceuticals SA Company Information
- 8.16.2 Cosmo Pharmaceuticals SA Business Overview
- 8.16.3 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.16.5 Cosmo Pharmaceuticals SA Recent Developments
- 8.17 Chugai Pharmaceutical
- 8.17.1 Chugai Pharmaceutical Company Information
- 8.17.2 Chugai Pharmaceutical Business Overview
- 8.17.3 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.17.5 Chugai Pharmaceutical Recent Developments
- 8.18 Bausch Health
- 8.18.1 Bausch Health Company Information
- 8.18.2 Bausch Health Business Overview
- 8.18.3 Bausch Health Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.18.5 Bausch Health Recent Developments
- 8.19 Allergens
- 8.19.1 Allergens Company Information
- 8.19.2 Allergens Business Overview
- 8.19.3 Allergens Chronic Idiopathic Constipation Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Allergens Chronic Idiopathic Constipation Drugs Product Portfolio
- 8.19.5 Allergens Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Chronic Idiopathic Constipation Drugs Value Chain Analysis
- 9.1.1 Chronic Idiopathic Constipation Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Chronic Idiopathic Constipation Drugs Production Mode & Process
- 9.2 Chronic Idiopathic Constipation Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Chronic Idiopathic Constipation Drugs Distributors
- 9.2.3 Chronic Idiopathic Constipation Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst